We previously demonstrated findings suggestive of autologous GVHD in patients receiving IL-2-activated peripheral blood stem cells (PBSC) with IL-2 after transplantation. A pilot study was designed to test tolerability, feasibility and frequency of autologous GVHD and engraftment using IL-2 and ␣-IFN posttransplantation. After cyclophosphamide (6 g/m and IIIB (n = 8) disease were treated. All patients were without evidence of disease at the time of transplantation. The average time required for the ANC to reach 500/mm 3 was 10 days (range: 8-11 days) and for platelets to reach 20 000/mm 3 was 10.7 days (range: 6-21 days). Forty-seven percent of patients (n = 16) completed the full course of immunotherapy; the remaining patients received attenuated doses due to patient's request (n = 6), development of temperature Ͼ38؇C (n = 3), development of neutropenia (n = 3), serious infection (n = 1) and miscellaneous reasons (n = 5). Four patients experienced transient moderate toxicities (level 3) including elevated liver function tests, nausea, rash and capillary leak syndrome. Pathological findings suggestive of skin GVHD developed in 43% of patients (12/28 patients) when skin biopsies were evaluated in a blinded fashion. At 13 months post-transplant (median; range: 5-24 months), 28 patients (82%) remain diseasefree. These results demonstrate the feasibility and toxicity of this regimen along with pathological findings compatible with autologous GVHD of the skin.
Hematopoietic stem cell (HSC) transplantation may improve disease-free survival for selected women with stage II-IV breast cancer. [1] [2] [3] Any attempt to further improve therapeutic efficacy by increasing chemotherapy dose may result in excessive nonhematologic toxicities. Immunomodulation, in conjunction with high-dose chemotherapy and HSC transplantation may offer a potential benefit by providing a non-cross-resistant mechanism of tumor cell kill with non-overlapping toxicities. In addition, immunotherapy following autologous HSC transplantation has been associated with the development of graft-versushost disease (GVHD). [4] [5] [6] The generation of autologous GVHD in patients undergoing autologous HSC transplantation using immunomodulation, has been described in patients with breast cancer, multiple myeloma, lymphoma and acute myelogenous leukemia. [7] [8] [9] [10] [11] [12] In the allogeneic BMT setting, the existence of GVHD is presumed to be associated with a graft-versus-tumor (GVT) effect, possibly contributing to the lower relapse rates. 13, 14 The co-existence of an autologous GVT effect in patients experiencing autologous GVHD is unknown.
When hematopoietic cells are incubated with IL-2 in vitro for 24 h, cytotoxic effector T cells are generated. [15] [16] [17] [18] These activated cells lyse NK-sensitive and NK-resistant tumor cells and result in an in vitro purging effect. 19, 20 Animal studies confirm these findings and demonstrate that the infusion of IL-2-activated autologous stem cells followed by low doses of parenteral IL-2 reduces tumor cell contamination within the graft and generates cytotoxic effector cells that mediate a GVT effect in vivo. [21] [22] [23] A previous phase I-II clinical trial with 61 patients demonstrated that the in vitro activation of autologous PBSC with IL-2, followed by the parenteral administration of IL-2 beginning the day of transplantation, did not delay engraftment and was associated with tolerable toxicities and side-effects in women with stage II-IV breast cancer. 4, 24 In addition, some patients demonstrated signs and symptoms of autologous GVHD of the skin. We have demonstrated synergistic tumor celldirected cytotoxicity and improved purging when PBSC are activated with the combination of IL-2 and ␣-interferon (␣-IFN) for 24 h in vitro compared to treatment with IL-2 alone. 19, 25 Because of the previous phase I/II clinical results and the positive laboratory results, this trial was designed to determine the tolerability, feasibility and frequency of autologous GVHD in breast cancer patients receiving IL-2 with ␣-IFN following infusion of IL-2-activated autologous PBSC.
Material and methods

Patient population
Thirty-four consecutive women with breast cancer meeting eligibility criteria were treated from July 1995 to January 1997. Patients with high risk stage II (у4 axillary lymph nodes involved with metastatic disease) or stage III disease were eligible. Since patients could be referred at any point during their therapy, patients could have received neoadjuvant chemotherapy, due to either the size of the primary tumor (stage IIIA) or due to aggressive inflammatory carcinoma (stage IIIB).
Eligibility criteria and staging evaluation
Patients were required to be at least 17 years of age, have adequate bone marrow, liver and renal function and no history of debilitating cardiac or pulmonary disease. A left ventricular ejection fraction of 50% or greater, as measured by radionuclide scan and pulmonary function tests demonstrating a forced expiratory volume (FEV 1 ) of Ͼ70% and a diffusion capacity Ͼ60% were needed. No radiographic evidence of malignant central nervous system involvement could exist and negative serologies for hepatitis B surface antigen, HIV and HTLV I were required. All patients needed a Karnofsky performance status of у80%. The protocol received institutional review board approval and all patients signed an informed consent.
The initial staging evaluation included a complete physical examination, chest radiograph, bone scan and computer tomographs of the head, thorax, abdomen and pelvis. An electrocardiogram and audiogram were performed. Laboratory evaluation included a complete blood count with differential and platelet count, coagulation profile, renal, liver, and thyroid function tests. In patients with measurable disease, baseline tumor measurements were obtained by physical examination and/or radiographic studies. All patients required a histologically negative bone marrow aspirate and biopsy.
Peripheral blood stem cell (PBSC) collection and harvest
Prior to the initiation of priming chemotherapy, a central venous catheter was inserted. Either cyclophosphamide (5 g/m 2 ) or paclitaxel (300-350 mg/m 2 over 24 h) was administered to mobilize PBSC. Recombinant human granulocyte colony-stimulating factor (rhG-CSF) (5 g/kg) was administered subcutaneously 48 h after the administration of priming chemotherapy and continued daily until completion of apheresis. Complete blood counts were obtained every other day until the start of apheresis.
PBSC collection was begun 24 h after return of the WBC to 1 ϫ 10 9 /l. Cells were collected using a Cobe Spectra cell separator (Cobe Laboratories, Lakewood, CO, USA) with anticoagulant citrate dextrose-formula A (ACD-A) (Baxter Healthcare, Deerfield, IL, USA). Three to four whole blood volumes (10-20 liters) were processed for each collection. Apheresis was continued until the following parameters were obtained: (1) 
Interleukin-2 activation of PBSC
The procedure used for IL-2 activation of PBSC has been described previously. 26 Briefly, 24 h prior to the PBSC infusion, the harvested cells were thawed rapidly in a 37°C water bath. The thawed cell suspension was incubated for 24 h in 5% CO 2 at 37°C in the serum-free medium X-VIVO 10 (BioWhittaker, Walkersville, MD, USA) containing gentamycin (50 g/ml), l-glutamine, heparin (50 units/ml) (Elkins-Simm, Cherry Hill, NJ, USA) and IL-2 (6000 IU/ml) (Chiron, Emeryville, CA, USA). Samples were obtained from the thawed cell suspension prior to IL-2 treatment and from the IL-2-activated cells and analyzed for cell count, viability, Gram stain, immunophenotyping, cytotoxicity assays and sterility (including testing for bacteria, fungi, mycoplasma and endotoxin). Approximately one-third of the PBSC were not cultured with IL-2 and were stored as back-up.
Treatment plan
Cyclophosphamide (2000 mg/m 2 ) and carboplatin (600 mg/m 2 ) were administered intravenously over 2 h on days Ϫ5, Ϫ4, and Ϫ3.
27 MESNA (sodium 2-mercaptoethane sulfonate) and hydration were given as prophylaxis for hemorrhagic cystitis. The anti-emetic regimen included ondansetron, lorazepam, and diphenhydramine.
On day 0, after 24 h of culture with IL-2, the activated PBSC were infused over 30-90 min at the patient's bedside with cardiovascular monitoring.
Subcutaneous IL-2 administration began on the day of transplantation at a dose of 6 ϫ 10 5 IU/m 2 /day and continued for 4 weeks. A week of therapy consisted of 5 days of treatment with 2 days of rest. After engraftment, ␣-IFN (Schering Plough, Kenilworth, NJ, USA) was initiated at a dose of 1 ϫ 10 6 IU/m 2 /day for 30 days. Engraftment was defined as an absolute neutrophil count of у500/mm 3 for 3 days and a platelet count of у20 000/mm 3 for 3 days (untransfused).
Toxicities were monitored daily and graded as follows: level 0 (no toxicity), level 1 (mild), level 2 and 3 (moderate), level 4 (severe) and level 5 (toxic death). If severe non-hematologic toxicities occurred during IL-2 therapy (у level 4), IL-2 was withheld. If the toxicities returned to level 1 (mild) or resolved, IL-2 was resumed. If signs and symptoms of the nonhematologic toxicities returned, the patient was removed from the study. No further IL-2 therapy was administered to patients with a dose-limiting toxicity that failed to resolve within 72 h.
Evaluation of autologous graft-versus-host disease
As part of the clinical trial, it was recommended that all patients have a baseline skin biopsy prior to high-dose chemotherapy. During their hospital stay, patients were examined by a bone marrow transplant physician daily and by a dermatologist three times each week. It was recommended that skin biopsies be performed weekly on patients during their 3-4 weeks of hospitalization. All biopsy specimens were reviewed by a pathologist. In addition, these slides were reviewed by a dermatopathologist in a blinded fashion. Using a scale developed by Horn, 28 each specimen was graded for the presence or absence of AuGVHD by using the following four criteria: basal cell vacuolization, exocytosis, presence of dyskeratotic cells and dermal lymphatic infiltration. Each criterion was scored as present or absent. Only the biopsy specimens demonstrating у3 of the four criteria were called positive and declared compatible with autologous GVHD of the skin. Controls consisted of biopsy specimens from the same patients prior to admission or at the time of admission but prior to the administration chemotherapy. In addition, normal skin from surgical specimens and baseline biopsy specimens from the same patients served as controls.
Supportive care
Patients were treated in HEPA-filtered rooms. Routine supportive care included at admission, trimethoprim/ sulfamethoxazole (one double strength tablet twice a day) for Pneumocystis carinii prophylaxis until day Ϫ1, norfloxacin for gastrointestinal bacterial decontamination, fluconazole (continued until day 30) and acyclovir until day 30. With the development of a temperature у38.5°C, broad spectrum antibiotics were initiated and norfloxacin discontinued. Amphotericin B was generally administered empirically when patients remained febrile after 48-72 h on broad spectrum antibiotic therapy.
All patients received daily rhG-CSF (5 g/kg/day) beginning on day 5 after transplantation and continued until the ANC reached 5.0 ϫ 10 9 /l for 2 days.
In-hospital clinical monitoring
Patients were evaluated daily during hospitalization by physical examination and blood work including a complete blood count with differential and platelet count, electrolytes, liver and renal function tests. Weekly tests included coagulation profile, chest radiograph and electrocardiogram. Packed red blood cells and single donor platelets were administered if the hemoglobin level fell below 8.5 g/dl or platelets dropped below 20 ϫ 10 9 /l, respectively, or for symptomatic anemia or bleeding.
Clinical monitoring after discharge
After discharge, patients were evaluated weekly in the outpatient clinic for 1 month and then returned to their referring oncologist. Evaluation at each clinic visit included a history and physical examination, a complete blood count with differential and platelet count, electrolytes, liver and renal function tests. Patients were evaluated for response 100 days after transplantation by physical examination, bone scan and CT scans of the thorax, abdomen and pelvis. Pulmonary function tests and a cardiac gated blood pool scan were also performed to determine if regimen-related toxicity had occurred. Re-evaluation was done every 6 months for the first 2 years and then yearly thereafter. Patients received ipsilateral chest wall, supraclavicular and axillary irradiation beginning 3 months after transplantation (total dose 5040 cGy chest wall). Patients with tumors expressing estrogen receptors were started on tamoxifen (10 mg twice a day) after completion of chest wall irradiation.
Statistical analysis
The Student's t-test was used for statistical analysis of the laboratory data. Disease-free and overall survivals were calculated from the day of transplantation using the method of Kaplan-Meier. This clinical trial was designed to assess the ability of IL-2-activated PBSC to reconstitute hematopoiesis, to investigate toxicities associated with the administration of IL-2 after transplantation, and to determine the side-effects of the combination of IL-2 with ␣-IFN and outcomes.
Results
Patient demographics
Thirty-four consecutive eligible patients with a mean age of 45.5 years (range 31-62 years) were treated. The patients had stage II (n = 20), stage IIIA (n = 6) and stage IIIB (n = 8) breast cancer. The patient population consisted of Caucasians (n = 27), African Americans (n = 3), Asians (n = 2) and Hispanics (n = 2). At the time of transplantation, all patients were without evidence of disease. Neoadjuvant chemotherapy (CAF) was administered to three women with stage II disease (mean four cycles; range 3-8 cycles) and seven patients with stage IIIB disease (mean four cycles; range 3-8 cycles). After surgery, chemotherapy was administered to 32 of 34 patients; 24 patients received CA(F) chemotherapy for four cycles (mean; range 1-4 cycles) and eight patients received three cycles of paclitaxel (mean; range 2-3 cycles). One patient proceeded on to priming chemotherapy with transplantation and another patient received radiation therapy and then went on to transplantation. Thirty-two of the patients received paclitaxel priming (300-350 mg/m 2 ) and two patients received cyclophosphamide (5 g/m 2 ).
Engraftment
All patients engrafted and back-up cell infusion was not required. The number of days required for the ANC to reach 0.5 ϫ 10 9 /l for 3 days was 10 days (mean; range 8-11 days). The average number of days for the platelet count to remain at 20 ϫ 10 9 /l for 3 days without transfusion support was 10.7 days (mean; range 6-21 days). The average length of stay, beginning on the day of admission for chemotherapy was 22.7 days (range 19 to 37 days). 
Toxicity
Toxicities are listed according to severity (mild, level 2 or moderate, level 3) in Table 1 . There were no toxic deaths. Ten patients developed a mild elevation in liver function tests (level 2) defined as a rise in bilirubin by 1-2 × normal and an elevation of SGOT and/or SGPT by 4-5 × normal. One patient developed a transient elevation in bilirubin Ͼ2.3 mg/dl, a rise in SGOT Ͼ210 IU/l and/or a rise in the alkaline phosphatase to Ͼ500 IU/l (level 3). Another patient developed transient infiltrates on chest X-ray and a deterioration in arterial oxygenation to 60-70 mmHg (level 3). One patient experienced symptomatic congestive heart failure (level 3) and was managed medically. Nausea and vomiting, consisting of two to five episodes of vomiting within 24 h, was observed in three patients (level 3). Three of the five patients who developed a skin rash had an erythematous maculopapular skin rash on more than 50% of their body (level 3). Nine patients experienced у1 l diarrhea for у24 h period (level 2). The majority of toxicities were observed with IL-2 therapy. Only four patients were removed from ␣-IFN therapy (see next section).
Withdrawal from immune therapy
Sixteen patients (47%) completed the full course of IL-2 and ␣-IFN therapy (Table 2) . Four patients received the full course of IL-2 but ␣-IFN was discontinued (average duration 13.3 days; range 2-23 days) due to depression (n = 1), patient request (n = 1), neutropenia (n = 1) and sepsis with hypotension (n = 1). Nine patients never received ␣-IFN and their IL-2 was discontinued (average duration 6.2 days; range 3.5-10.5 days) due to patient request (n = 4), fever Ͼ39°C for 48 h (n = 3), abdominal pain (n = 1) or hemolysis (n = 1). Five additional patients received a shortened dose of IL-2 (mean duration of therapy, 11.5 days, range 8-16 days) and ␣-IFN (mean duration of therapy 10.4 days, range 1-20 days) for leukopenia (n = 2), patient request (n = 1), fevers (n = 1), and severe skin rash (n = 1).
Cell recovery, viability and progenitor cell culture of PBSC products
The pre-and post-IL-2-activated PBSC samples from all patients were analyzed. After 24 h of incubation with IL-2, there was 69.2% recovery of cells demonstrating у90% viability. This represented a decrease in the number of mononuclear cells/kg from the pre-activation samples of 3.71 ϫ 10 8 cells/kg (mean) to the post-activation samples of 2.49 ϫ 10 8 cells/kg (mean; P value Ͻ0.0001). The number of CD34 + cells/kg decreased from the pre-activation samples (mean: 9.24 ϫ 10 6 cells/kg) to the post-activation samples (mean: 7.34 ϫ 10 6 cells/kg; P value Ͻ0.0001).
There was no significant change in the number of CFU-GM/kg (mean, 68.05 ϫ 10 5 /kg).
Autologous graft-versus-host disease
Twenty-eight patients had skin biopsies (average: two samples/patient; range 1-4 biopsies per patient) within 4 weeks of transplant. The skin biopsies from 43% of patients (12 of 28 patients) demonstrated histological findings compatible with GVHD. However, in three patients, biopsies that were read as positive were obtained between day 0 and day 2. Biopsies consistent with GVHD were obtained 11.3 days (average; range 2 to 35 days) after transplantation. The rashes were self-limiting, generally resolving within days of discontinuing immunotherapy. Only three patients experienced the development of rash on Ͼ50% of their body (level 3 toxicity).
Outcome
The disease-free survival and survival curves given in Figure 1 indicate that at 1 year following transplantation, 88% of patients are disease-free and 100% of patients are alive. Since only nine patients have been on study for longer than 1 year, estimates subsequent to 12 months are subject to variability. The follow-up period ranges from 5 to 24 months (mean 12.8 months). Five of 34 patients relapsed, two patients locally and three patients systemically. An additional patient developed a new breast primary in the contralateral breast. Of the five relapsed patients, one patient with stage II disease recurred locally at 14 months. Another patient with stage IIIB disease developed local recurrence of the skin 6 months following transplant and prior to initiation of XRT. Three patients (stage II, n = 1; stage IIIA, n = 1; and stage IIIB, n = 1) experienced systemic relapses 12.5 months (median; range 12-13 months) after transplantation including metastases to the lungs (n = 2) and lung with bone (n = 1). The remaining 29 patients remain disease-free with a median follow-up of 12.8 months. Two of the three patients who developed systemic relapse died 16.5 months post-trans- 
Discussion
This clinical trial was designed to determine the tolerability and feasibility of breast cancer patients receiving IL-2 with ␣-IFN following infusion of IL-2-activated autologous PBSC. Also, we wanted to determine the frequency of autologous GVHD.
Thirty-four consecutive patients with stage II-III breast cancer were treated on this regimen. Engraftment occurred in all patients, demonstrating that the infusion of IL-2-activated autologous PBSC with the parenteral administration of IL-2 and ␣-IFN can be safely used in this setting. The toxicities were transient and generally occurred with IL-2 therapy and subsided within days after discontinuation of IL-2 and/or ␣-IFN. Forty-seven percent of patients completed the planned course of immune therapy, with the remaining patients experiencing toxicities requiring discontinuation of IL-2 and/or ␣-IFN. Seven of the 18 patients removed did not meet removal criteria but requested removal primarily due to persistent fatigue and lethargy. The cell recovery and viability after IL-2 activation were comparable with previous results and show a mild decrease in mononuclear cell number with slight decrease in CD34 + cell content. 29, 30 Although patient follow-up is short (median, 12.8 months), the overall and disease-free survival rates for these women are comparable to results in the literature 1 at similar follow-up. Definitive conclusions will require long-term follow-up.
Forty-three percent of these patients had pathological findings on skin biopsies compatible with autologous GVHD. It is not known if the finding of AuGVHD is associated with an autologous graft-versus-tumor (GVT) effect. It is intriguing to note that 10 of 12 patients experiencing autologous GVHD remain disease-free. Current laboratory evaluations are exploring this possibility. Histologic findings consistent with autologous GVHD were observed in seven skin biopsy specimens from patients with a normal skin examination. This is not an unusual finding in patients receiving immune therapy following autologous hematopoietic stem cell transplantation and has been described by others. 8, 11 This raises the question of whether a GVT effect can occur without clinical evidence of GVHD. In addition, we may have underestimated the frequency of autologous GVHD in our patients since some patients only had one biopsy specimen obtained, and others developed a skin rash but histologic examination demonstrated only two of the four required findings.
Our clinical trial differs from other studies evaluating immune therapy in breast cancer patients following HSC transplantation. We selected the combination of IL-2 and ␣-IFN due to the in vitro synergetic tumor-cell directed cytotoxicity. 19, 25 IL-2 and ␣-IFN have been used in patients with lymphoma following autologous bone marrow or stem cell transplantation. These patients experienced improved disease-free and overall survivals (P = 0.01) when compared to a control group of patients not receiving immuno-therapy. 31 Cyclosporine (CsA) has been the most commonly used immune modulator in breast cancer patients receiving autologous BMT. It is postulated that CsA inhibits clonal deletion of prethymic autoreactive T cells. 32 As a result, autoreactive T cells are generated with the use of CsA and these cells demonstrate antitumor activity against cells bearing MHC class II antigens. These T cells will destroy cells expressing the MHC class II antigens, including tumor cells. Gamma IFN (␥-IFN) will up-regulate MHC class II expression on cells. The combination of ␥-IFN and CsA has been used in breast cancer patients receiving autologous BMT in an attempt to enhance tumor cell kill. 33 The mechanism of action of IL-2-activated autologous PBSC used in this trial does not depend upon MHC expression. Activating PBSC in IL-2 for 24 h generates cytotoxic T cells with the CD3 + , CD25 + (IL-2 receptor) and HLA-DR phenotype. 4 These cytotoxic T cells lyse NKsensitive and NK-resistant cell lines and two breast cancer cell lines, SKBr-3.0 and MCF-7 cells. 4 The IL-2-activated PBSC result in an in vitro purging of malignant cells contaminating the PBSC, and may possess potential in vivo GVT effects. Animal data support the critical need for the combination of in vitro activation of stem cells with IL-2 followed by the administration of IL-2 to maintain the in vivo cytotoxic potential of the activated cells with insufficient effects using either process alone. 21, 34 The addition of ␣-IFN to IL-2 in vitro results in a synergistic cytotoxic effect against various tumor cell lines, including breast cancer cell lines. 19, 25 Since we were concerned that the combination of parenterally administered IL-2 and ␣-IFN might be too toxic early after transplantation and may result in suppression of hematopoiesis, we initiated ␣-IFN after engraftment. We hoped the combination of IL-2 with ␣-IFN would result in beneficial in vivo GVT effect.
The regimen employed in this clinical trial is also different from LAK cell therapy. LAK cell infusion or IL-2 administration after transplantation has been used in the treatment of both solid tumors and hematologic malignancies. [35] [36] [37] [38] [39] IL-2-activated PBSC require a much lower dose of IL-2 to be generated in vivo and can be generated within 24 h of incubation. IL-2-activated PBSC also possess enhanced cytotoxicity against human tumor cell lines when compared to peripheral blood LAK cells. 15, 40 This study demonstrates successful engraftment with IL-2-activated PBSC after high-dose chemotherapy for women with stage II-III breast cancer with the development of selflimiting autologous GVHD of the skin. The regimen resulted in only 47% of patients completing the full course of therapy. Future trials will need to address dose modifications and timing of IL-2 with ␣-IFN. It does not appear that the combination of IL-2 with ␣-IFN resulted in excessive toxicity since only five of 34 patients were removed from protocol at the time they were receiving both agents. Both clinical and laboratory studies are being pursued to examine the existence of an autologous GVT effect and the associated mechanisms in women with breast cancer undergoing PBSC transplantation with this regimen.
